Shanghai Pioneer Holding Yönetim
Yönetim kriter kontrolleri 3/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Steven Yang
İcra Kurulu Başkanı
CN¥655.0k
Toplam tazminat
| CEO maaş yüzdesi | 78.8% |
| CEO görev süresi | 1.6yrs |
| CEO sahipliği | n/a |
| Yönetim ortalama görev süresi | 4.5yrs |
| Yönetim Kurulu ortalama görev süresi | 2.9yrs |
Son yönetim güncellemeleri
Recent updates
Shareholders Should Be Pleased With Shanghai Pioneer Holding Ltd's (HKG:1345) Price
Jul 15
Shanghai Pioneer Holding's (HKG:1345) Dividend Will Be CN¥0.024
Apr 24Shanghai Pioneer Holding (HKG:1345) Will Pay A Dividend Of CN¥0.024
Apr 03Shanghai Pioneer Holding's (HKG:1345) Shareholders Have More To Worry About Than Only Soft Earnings
Apr 01Shanghai Pioneer Holding Ltd (HKG:1345) Could Be Riskier Than It Looks
Mar 22Shanghai Pioneer Holding (HKG:1345) Is Finding It Tricky To Allocate Its Capital
Feb 26Does Shanghai Pioneer Holding (HKG:1345) Have A Healthy Balance Sheet?
Oct 21Shanghai Pioneer Holding (HKG:1345) Has Announced That It Will Be Increasing Its Dividend To CN¥0.024
Sep 18Shanghai Pioneer Holding (HKG:1345) Is Increasing Its Dividend To CN¥0.024
Sep 01Here's Why We Think Shanghai Pioneer Holding (HKG:1345) Is Well Worth Watching
Aug 09Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Apr 14Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Mar 31Shanghai Pioneer Holding (HKG:1345) Seems To Use Debt Rather Sparingly
Dec 15China Pioneer Pharma Holdings' (HKG:1345) Dividend Will Be Reduced To CN¥0.018
Sep 21China Pioneer Pharma Holdings' (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Sep 02China Pioneer Pharma Holdings (HKG:1345) Has More To Do To Multiply In Value Going Forward
Jun 22China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.064
Apr 14China Pioneer Pharma Holdings (HKG:1345) Will Be Hoping To Turn Its Returns On Capital Around
Jan 16These 4 Measures Indicate That China Pioneer Pharma Holdings (HKG:1345) Is Using Debt Safely
Oct 11China Pioneer Pharma Holdings (HKG:1345) Is Paying Out Less In Dividends Than Last Year
Sep 15China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.056
Sep 01China Pioneer Pharma Holdings (HKG:1345) Will Be Looking To Turn Around Its Returns
Aug 26Returns On Capital At China Pioneer Pharma Holdings (HKG:1345) Paint A Concerning Picture
May 22We Think China Pioneer Pharma Holdings (HKG:1345) Can Stay On Top Of Its Debt
Apr 25Can Mixed Financials Have A Negative Impact on China Pioneer Pharma Holdings Limited's 's (HKG:1345) Current Price Momentum?
Mar 14How Has China Pioneer Pharma Holdings (HKG:1345) Allocated Its Capital?
Feb 21
Should You Use China Pioneer Pharma Holdings' (HKG:1345) Statutory Earnings To Analyse It?
Feb 03Is China Pioneer Pharma Holdings Limited (HKG:1345) At Risk Of Cutting Its Dividend?
Jan 16China Pioneer Pharma Holdings (HKG:1345) Has A Rock Solid Balance Sheet
Dec 29Is China Pioneer Pharma Holdings Limited's (HKG:1345) Stock Price Struggling As A Result Of Its Mixed Financials?
Dec 14China Pioneer Pharma Holdings (HKG:1345) Has Gifted Shareholders With A Fantastic 124% Total Return On Their Investment
Nov 29CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥164m |
| Mar 31 2024 | n/a | n/a | CN¥155m |
| Dec 31 2023 | CN¥655k | CN¥516k | CN¥146m |
| Sep 30 2023 | n/a | n/a | CN¥168m |
| Jun 30 2023 | n/a | n/a | CN¥190m |
| Mar 31 2023 | n/a | n/a | CN¥213m |
| Dec 31 2022 | CN¥752k | CN¥624k | CN¥235m |
Tazminat ve Piyasa: Steven 'nin toplam tazminatı ($USD 91.98K ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 359.95K ).
Tazminat ve Kazançlar: Steven 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Steven Yang (36 yo)
1.6yrs
Görev süresi
CN¥655,000
Tazminat
Mr. Yuewen Yang, also known as Steven, serves as Chief Executive Officer since April 2023 and serves as its Executive Director since September 16, 2022 and served as Chief Operating Officer at Shanghai Pio...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman | 11.8yrs | CN¥2.05m | 0.95% HK$ 22.2m | |
| CEO & Executive Director | 1.6yrs | CN¥655.00k | Veri yok | |
| General Manager of Dental Business Division & Executive Director | 3.3yrs | CN¥717.00k | Veri yok | |
| Chief Financial Officer | 7.9yrs | Veri yok | Veri yok | |
| General Manager of Investment Unit | no data | Veri yok | Veri yok | |
| Director of Personnel | no data | Veri yok | Veri yok | |
| Company Secretary | 5.7yrs | Veri yok | Veri yok |
4.5yrs
Ortalama Görev Süresi
49yo
Ortalama Yaş
Deneyimli Yönetim: 1345 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.5 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman | 11.8yrs | CN¥2.05m | 0.95% HK$ 22.2m | |
| CEO & Executive Director | 2.2yrs | CN¥655.00k | Veri yok | |
| General Manager of Dental Business Division & Executive Director | 1.1yrs | CN¥717.00k | Veri yok | |
| Independent Non-Executive Director | 2.9yrs | CN¥270.00k | Veri yok | |
| Independent Non-Executive Director | 5.8yrs | Veri yok | Veri yok | |
| Non-Executive Director | 3.9yrs | CN¥184.00k | Veri yok | |
| Independent Non-Executive Director | less than a year | Veri yok | Veri yok |
2.9yrs
Ortalama Görev Süresi
60yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: 1345 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.9 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.